Nuvectis Pharma Shares Surge on Strategic Haisco Licensing Deal and Analyst Upgrades

Key Facts

1Nuvectis Pharma secured exclusive rights outside China for two experimental drugs, NXP100 and NXP200, from Haisco Pharmaceutical Group.

2Roth Capital raised its price target for NVCT to $33.00 from $20.00 while maintaining a Buy rating.

3The agreement elevates Nuvectis to a late-stage clinical development company, expanding its oncology and complement-mediated disease portfolio.

In a move reflecting the accelerating pace of innovation within the biotechnology sector, Nuvectis Pharma announced a strategic licensing agreement with China's Haisco Pharmaceutical Group. Under the deal, Nuvectis secured exclusive rights outside China for two experimental drug candidates, NXP100 and NXP200. This agreement elevates Nuvectis to a late-stage clinical development company, significantly strengthening its oncology and complement-mediated disease portfolio.

This development comes as the biotech sector sees intensified efforts to expand pipelines; consequently, Roth Capital raised its price target for NVCT to $33.00 from $20.00 while maintaining a Buy rating, per market data. Compared to peers in similar clinical stages, this pipeline expansion positions Nuvectis more competitively, particularly within the high-interest oncology space that continues to attract significant investor capital.

According to market data, NVCT closed at $19.57 (close July 02, 2026), having reached a day high of $20.35. Traders are now watching for resistance levels near the newly issued analyst targets, while the broader market awaits key macroeconomic catalysts, such as the upcoming U.S. CB Consumer Confidence data, which may influence risk appetite across the growth-oriented biotech sector.